Public procurement notice: Voluntary Ex Ante Transparency Notice
Published: 2017-09-15
Buyer: Oslo universitetssykehus HF
Country: NO
Contract type: Supplies
Procedure: Negotiated without a prior call for competition
CPV classification: 33100000
Estimated value: 25000000 NOK

Technical requirements: Oslo University Hospital, Medical Biochemistry Department, Section for haemostasis and thrombosis, has had an acute breakdown of one of the instruments that are used for special coagulation analyses. The establishment of new reference areas and new measuring methods is very time consuming.
As the situation is acute, OUS must procure an instrument that can carry out the special coagulation analyses with the same reference areas and the same measuring methods that OUS currently uses.
The analyses that are carried out on the instruments are used, amongst other things, for studying increased bleeding tendencies (exclude/diagnose haemophilia disease) and increased thrombosis tendencies and delayed diagnosis can be critical for many patients.
Oslo University Hospital, Medical Biochemistry Department, Section for haemostasis and thrombosis, has had an acute breakdown of one of the instruments that are used for special coagulation analyses. The establishment of new reference areas and new measuring methods is very time consuming.
As the situation is acute, OUS must procure an instrument that can carry out the special coagulation analyses with the same reference areas and the same measuring methods that OUS currently uses.
The analyses that are carried out on the instruments are used, amongst other things, for studying increased bleeding tendencies (exclude/diagnose haemophilia disease) and increased thrombosis tendencies and delayed diagnosis can be critical for many patients.
The Blood Diseases Department at OUS-Rikshospitalet has a national function for haemophilia disease and several of the analyses for investigating increased bleeding tendencies are only carried out at our laboratory in Norway. The analysis results are also used to monitor treatment (the effect of factor concentrate) in patients with haemophilia disease. Most major operations on patients with haemophilia disease are carried out at Oslo University Hospital and an analysis of the activity of the affected coagulation factor is an important part of such interventions. Analysis results are urgent for operations/complications in haemophilia patients and we must know that we can provide quick results in cases of acute bleeding problems. As coagulation samples have a shorter shelf life that many other clinical chemical analyses, we also risk the samples being ruined if they are left standing for too long on the worktop due to one instrument being out of action. The instrument shall also be used for investigating increased thrombosis tendencies. The section has a very high number of samples that are sent every year and, as a result of this, comprehensive commenting. Short interruptions can quickly result in long and unpredictable response times and a bad service for requisitioners and patients.
The 3 instruments that OUS uses for the analysis of special coagulation analyses are back up for each other and it is therefore important that the analyses on the new instrument have the same level and precision as the other instruments, so that we can use the same reference areas and control rules on all the instruments. The introduction of a reference area and the establishment of new measuring methods are very time consuming. The use of different types of anti-coagulants can interfere in the measuring methods and give errors in the sample results. OUS has, therefore, made routines to intercept the presence of anti-coagulants in the samples. It is a known fact that anti-coagulants can affect different reagents/measuring methods in different ways. It is important to use measuring methods / reagents where the different types of anti-coagulants interfere in the same way on all 3 instruments — so that we can use the same routines for discovering interference of anti-coagulants on all the instruments.
Coagulation factor activity for I-XII (clotting method) (It is important that the FVIII and FIX methods can be used to diagnose serious haemophilia < 1,0 IU/dL). Factor sensitive APTT, Protrombintid Quick, Kromogen FVIII activity, Antithrombin activity (FXa based reagent), free protein S, protein C activity, Lupus anti-coagulant (screen and confirm test for two sub-tests for lupus anti-coagulant (dRVVT and an APTT based method).
We currently carry out approx. 2000-2500 Factor VIII and Factor IX activities/annum and 6000-7000 Antithrombin, free protein S, protein C activities/annum as well as 4000-5000 Lupus anti-coagulants / annum.
This is based on ACC Nordic AS being the only supplier that can provide the delivery, due to technical reasons. The terms in the PPR § 13-4 (2) and 13-3 (1) are considered to be fulfilled.
The procurement's value includes the procurement of equipment specific consumables for as long as the instrument is in use, as well as the value of a full service contract for the instrument's lifetime.
There has been an acute breakdown of one of the instruments used for special coagulation analyses. The establishment of new reference areas and new measuring methods is very time consuming.
As the situation is acute, OUS must procure an instrument that can carry out the special coagulation analyses with the same reference areas and the same measuring methods that OUS currently uses.


Winner: ACC Nordic AS
Award value: 25000000